The Top 5 Biosimilar Articles for the Week of August 25

August 29, 2025

Here are the top 5 biosimilar articles for the week of August 25, 2025.

Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

August 27, 2025

Canadian RWE Shows Comparable Outcomes Between Etanercept Biosimilars, Originator

August 26, 2025

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP

August 25, 2025

The Top 5 Biosimilar Articles for the Week of August 18

August 22, 2025

Robert F. Kennedy Jr Confirmed as HHS Secretary, Nearly Along Party Lines

February 13th 2025

By Christina Mattina

Article

The Senate voted 52-48 to confirm Robert F. Kennedy Jr as secretary of HHS, setting up the vaccine skeptic to carry out major changes in pursuit of his Make America Healthy Again agenda.

Psoriasis Biosimilars Saved VA $67 Million in 2023

February 12th 2025

By Skylar Jeremias

Article

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high costs of biologic therapies to treat chronic disease.

The Future of Pharmacy: Trends, Threats, Transformations

February 11th 2025

By Cameron Santoro

Article

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access and affordability for patients across the nation.

Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market Potential

February 10th 2025

By Dracey Poore

Article

2025 marks a pivotal year for biosimilars with Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey Poore, MS, of Cardinal Health.

Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals

February 9th 2025

By Skylar Jeremias

Podcast

In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.

Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer

February 8th 2025

By Deana Ferreri, PhD

Article

A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.

The Top 5 Biosimilar Articles for the Week of February 3

February 7th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of February 3, 2025.

CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets

February 6th 2025

By Skylar Jeremias

Article

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.

Interchangeable Aflibercept Biosimilar, Enzeevu, Comparable With Eylea for nAMD

February 6th 2025

By Cameron Santoro

Article

Enzeevu (aflibercept-abzv), a biosimilar developed by Sandoz, demonstrated biosimilarity to reference aflibercept (Eylea) in patients with neovascular age-related macular degeneration (nAMD).

The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars

February 5th 2025

By Skylar Jeremias

Article

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.